弥散相关光谱评估小鼠模型中的脑血流

Executive Industry Relevance

Diffuse correlation spectroscopy (DCS) provides a non-invasive, real-time method for assessing cerebral blood flow in preclinical models, supporting target validation in neuroinflammatory and hemodynamic studies. The technique enables mechanistic de-risking by quantifying microvascular perfusion dynamics without surgical intervention, offering predictive value for TBI therapeutic screening. Its compatibility with anesthetized mouse models allows integration into early discovery workflows for pathway clarification and biomarker alignment.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by measuring cerebral blood flow as a functional readout of neurovascular response to injury.
• Operational Value: Supports biological de-risking through non-invasive, longitudinal monitoring of hemodynamic changes in disease models.
• Predictive Value: Provides quantitative hemodynamic data to prioritize targets with strong pathophysiological relevance in TBI models.

Screening & Assay Development

• Assay Readiness: Generates reproducible cerebral blood flow index measurements suitable for standardization across experimental groups.
• Scalability: Facilitates rapid hemispheric comparisons within single sessions, supporting high-throughput hemodynamic screening.
• Platform Reuse: Compatible with repeated measurements over time, enabling dose-response and temporal profiling in pharmacological studies.

Translational & Preclinical Research

• Disease Relevance: Models mild traumatic brain injury pathophysiology by capturing acute hemodynamic fluctuations in vivo.
• Translational Continuity: Bridges discovery and preclinical validation by providing a clinically translatable perfusion metric.
• Risk-Adjusted Advancement: Hemodynamic stability or normalization can serve as a pharmacodynamic biomarker for go/no-go decisions.

Pipeline & Workflow Integration

DCS fits within the discovery continuum from target validation through preclinical assessment, offering a non-invasive hemodynamic readout that complements molecular and behavioral endpoints in TBI models.

• Discovery Biology: Supports hypothesis testing by linking interventions to measurable changes in cerebral perfusion, clarifying neurovascular pathway involvement.
• Screening: Delivers standardized, quantitative blood flow index outputs that enable reliable comparison of compound effects across hemispheres and time points.
• Analytics: The autocorrelator-derived intensity autocorrelation function provides a robust statistical output for condition comparison and variability assessment.
• Translational Research: Cerebral blood flow index serves as a translational biomarker with potential alignment to clinical neuroimaging modalities.
• Enterprise Reuse: The DCS platform can be standardized across labs and studies, reducing variability in hemodynamic phenotyping.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in neurovascular responses to TBI interventions.
• Operational Value: Ensures reproducibility through standardized probe placement, light shielding, and acquisition protocols.
• Strategic Value: Improves go/no-go decisions by providing objective hemodynamic data, reducing late-stage failure risk due to unanticipated vascular effects.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on cerebral perfusion profiles in disease-relevant models.

Implementation Considerations

• Requires expertise in optical imaging and anesthetic management for stable murine preparations.
• Depends on laser source, fiber-optic probe, avalanche photodiode, and autocorrelator infrastructure.
• Necessitates cross-team standardization of sensor alignment and ambient light control for consistent results.
• Adaptation across models may require adjustments to probe spacing and acquisition duration based on skull thickness and vascular density.
• Practical limitations include signal attenuation from hair or scalp reflectance, mitigated by shaving and optical coupling.

Biopharma FAQs